Abstract
The global pharmaceutical pricing and reimbursement environment is notoriously
complex and continuously changing. Pharma companies must implement strategic
pricing assessments across global markets and product lifecycle phases in
order to develop effective pricing policies. By incorporating such assessments
into portfolio evaluations and lifecycle planning, companies can enhance their
understanding of potential price profiles for individual drugs and optimise
future returns. ' Pharmaceutical Pricing and Reimbursement' is a new report
published by Business Insights that examines the tactical importance of price
optimization throughout the product lifecycle. The key issues affecting
pricing and reimbursement disciplines are identified and the market
environments of individual countries are assessed. This report will also
detail the global and lifecycle pricing strategies of new and established
drugs, including actionable recommendations and detailed case studies, and
provide forecasts for future pricing scenarios in major markets.
Table of Contents
Executive Summary
- An introduction to price optimization
- Pricing and reimbursement in North America
- Pricing and reimbursement in Europe
- Pricing and reimbursement in Japan and the rest of the world
- Global pricing strategies
- Lifecycle pricing strategies
Chapter 1 An introduction to price optimization
- Summary
- Introduction
- Delivering a return on investment
- Sustained R&D productivity shortfall
- Impending blockbuster patent expiries
- Healthcare cost containment
- Cost-containment initiatives
- Pharmaceutical spend cost containment
- Key issues impacting on pricing
- Pharmaceutical price optimization
- Pricing and reimbursement regulations
- Reference pricing
- Pharmacoeconomic evaluations
- Parallel imports and reimportation
- Generic substitution
- Global versus lifecycle pricing
Chapter 2 Pricing and reimbursement in North America
- Summary
- Introduction
- US pricing regulations
- Medicare
- Medicaid
- Private healthcare
- Pharmacoeconomics
- Generic substitution
- Recent developments in the US
- Medicare Part B revisions
- Medicare Part D - one year on
- Average manufacturer price
- Re-importation in decline
- Follow-on biologics
- Reverse payments to generic companies
- Future pricing scenarios in the US
- Best case pricing scenario
- Worst case pricing scenario
- Most likely pricing scenario
- Canadian pricing regulations
- Federal measures
- Provincial measures
- Common drug review expansion
- Patented Medicine Price Review Board progress
Chapter 3 Pricing and reimbursement in Europe
- Summary
- Introduction
- European pricing regulations
- French pricing regulations
- State of the industry
- Recent developments in France
- Parallel trade
- Generic substitution
- German pricing regulations
- State of the industry
- Recent developments in Germany
- The Statutory Health Insurance Competition Enhancement law
- Italian pricing regulations
- State of the industry
- Recent developments in Italy
- Regional cost-containment
- 2007 Finance Law
- Spanish pricing regulations
- State of the industry
- Recent developments in Spain
- Regional cost-containment
- Modified reference price system
- Anti-parallel trade strategies
- UK pricing regulations
- Recent developments in the UK
- The future of the PPRS
- Risk sharing schemes
- Declining parallel trade
- Expanding the NICE remit
- Future pricing scenarios in Europe
- Best case pricing scenario
- Worst case pricing scenario
- Most likely pricing scenario
Chapter 4 Pricing and reimbursement in Japan and the rest of the world
- Summary
- Introduction
- Japanese pricing regulations
- Recent developments in Japan
- Biennial price cut
- Generic substitution introduced
- Future pricing scenarios in Japan
- Best case pricing scenario
- Worst case pricing scenario
- Most likely pricing scenario
- Australian pricing regulations
- Benchmark pricing
- Cost plus method
- Average monthly treatment cost
- Prices for new items
- Recent developments in Australia
- Pharmaceutical Benefits Scheme reform
- Chinese pricing regulations
- Recent developments in China
- New drug pricing procedures
- Price cuts
- Generic prescribing
Chapter 5 Global pricing strategies
- Summary
- Introduction
- Local optimization
- Market access and reimbursement
- Free price markets
- Orphan drugs
- Pharmacoeconomic evaluations
- Global coordination
- Launch sequence
- Optimal price differentials
- Implementing global pricing strategies
Chapter 6 Lifecycle pricing strategies
- Summary
- Introduction
- Launch phase pricing considerations
- Submission dossiers
- Identifying key decision makers
- Failure to secure reimbursement
- Working with decision makers
- Applying pressure through lobbying
- Brokering deals
- Patent protected phase pricing considerations
- Case study: the respiratory market
- Innovative pricing strategies
- Patent expiry phase pricing considerations
- Price changes
- US patent expiry
- European patent expiry
- Case study: generic simvastatin
- Biosimilar pricing
- Implementing lifecycle pricing strategies
Chapter 7 Appendix
List of Figures
- Figure 1.1: Declining trend in number of NDA and NME approvals, 1997-2006
- Figure 1.2: Rise in the cost of drug development, 1975-2001
- Figure 1.3: US patent expiries for top ten selling drugs, 2006-2011
- Figure 1.4: Trends in healthcare spending as a proportion of GDP, 1970-2005
- Figure 1.5: Pharmaceutical expenditure as a share of total healthcare
expenditure in 2005
- Figure 2.6: Source of prescription drug expenditures, 2005-2006
- Figure 2.7: Canadian cross border internet pharmacy sales, 2002-2006
- Figure 2.8: Compensatory final settlements (reverse payments), 2004-2006
- Figure 3.9: Average ex-factory drug prices in key European markets, 2005
- Figure 4.10: NHI price cuts by therapeutic class, 2006
- Figure 5.11: Market share for new products launched in last five years,
2005
- Figure 5.12: External reference pricing in Europe, 2007
- Figure 5.13: Global pricing and the interaction between countries
- Figure 5.14: Global pricing strategies
- Figure 6.15: Leading respiratory drugs by global sales, 2006
- Figure 6.16: Lifecycle pricing strategies
List of Tables
- Table 1.1: Number of NDA and NME approvals by the FDA, 1990-2006
- Table 1.2: R&D expenditure within the US and abroad by PhRMA members,
1980-2006
- Table 1.3: Trends in healthcare spending as a proportion of GDP, 1970-2005
(%)
- Table 2.4: Future pricing scenarios in the US
- Table 3.5: Future pricing scenarios in Europe
- Table 4.6: Co-payments for drugs/services in Japan
- Table 4.7: Classification for price premium (Japanese healthcare system)
- Table 4.8: Future pricing scenarios in Japan
医薬品
その他のカテゴリ
FAQ